{"preliminary_commentary":{"by_channel":{"youtube":10,"podcast":4,"x_thread":4,"bluesky_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06580314\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"NRG-GY036","nct_id":"NCT06580314","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nrg-gy036-nct06580314. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive olaparib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may also receive bevacizumab IV on day 1 of each cycle. Cycles of bevacizumab repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and CT and/or MRI throughout the study.","label":"Arm I (olaparib, bevacizumab)","type":"ACTIVE_COMPARATOR"},{"description":"Patients receive olaparib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients may also receive bevacizumab IV on day 1 of each cycle. Cycles of bevacizumab repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and CT and/or MRI throughout the study.","label":"Arm II (olaparib, bevacizumab)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2034-12-31","type":"ESTIMATED"},"conditions":["Fallopian Tube Endometrioid Adenocarcinoma","Fallopian Tube High Grade Serous Adenocarcinoma","Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor","FIGO Stage III Ovarian Cancer 2014","FIGO Stage IV Ovarian Cancer 2014","Ovarian Carcinoma","Ovarian Carcinosarcoma","Ovarian High Grade Endometrioid Adenocarcinoma","Ovarian High Grade Serous Adenocarcinoma","Primary Peritoneal Carcinosarcoma","Primary Peritoneal Endometrioid Adenocarcinoma","Primary Peritoneal High Grade Serous Adenocarcinoma"],"enrollment":{"count":880,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Bevacizumab","otherNames":["ABP 215","ABP-215","ABP215","Alymsys","Anti-VEGF","Anti-VEGF Humanized Monoclonal Antibody","Anti-VEGF Monoclonal Antibody SIBP04","Anti-VEGF rhuMAb","Avastin","Avegra","Avzivi","Aybintio","BAT 1706","BAT-1706","BAT1706","BAT1706 Biosimilar","Bevacizumab awwb","Bevacizumab Biosimilar ABP 215","Bevacizumab Biosimilar BAT1706","Bevacizumab Biosimilar BEVZ92","Bevacizumab Biosimilar BI 695502","Bevacizumab Biosimilar CBT 124","Bevacizumab Biosimilar CT-P16","Bevacizumab Biosimilar FKB238","Bevacizumab Biosimilar GB-222","Bevacizumab Biosimilar HD204","Bevacizumab Biosimilar HLX04","Bevacizumab Biosimilar IBI305","Bevacizumab Biosimilar LY01008","Bevacizumab Biosimilar MB02","Bevacizumab Biosimilar MIL60","Bevacizumab Biosimilar Mvasi","Bevacizumab Biosimilar MYL-1402O","Bevacizumab Biosimilar QL 1101","Bevacizumab Biosimilar QL1101","Bevacizumab Biosimilar RPH-001","Bevacizumab Biosimilar SCT501","Bevacizumab Biosimilar Zirabev","Bevacizumab-adcd","Bevacizumab-aveg","Bevacizumab-awwb","Bevacizumab-aybi","Bevacizumab-bvzr","Bevacizumab-byva","Bevacizumab-equi","Bevacizumab-maly","Bevacizumab-nwgd","Bevacizumab-onbe","Bevacizumab-tnjn","BP102","BP102 Biosimilar","Byvasda","CT P16","CT-P16","CTP16","Equidacent","FKB 238","FKB-238","FKB238","HD204","IBI 305","IBI-305","IBI305","Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer","Jobevne","MB 02","MB-02","MB02","Mvasi","MYL-1402O","Onbevzi","Oyavas","PF 06439535","PF-06439535","PF06439535","QL1101","Recombinant Humanized Anti-VEGF Monoclonal Antibody","rhuMab-VEGF","SCT501","SIBP 04","SIBP-04","SIBP04","Vegzelma","Zirabev"],"type":"BIOLOGICAL"},{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Sample Collection","Specimen Collection"],"type":"PROCEDURE"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","Diagnostic CAT Scan","Diagnostic CAT Scan Service Type","tomography"],"type":"PROCEDURE"},{"name":"Magnetic Resonance Imaging","otherNames":["Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"],"type":"PROCEDURE"},{"name":"Olaparib","otherNames":["AZD 2281","AZD-2281","AZD2281","KU 0059436","KU-0059436","KU0059436","Lynparza","Olanib","Olaparix","PARP Inhibitor AZD2281"],"type":"DRUG"}],"last_update":"2026-08-07","lead_sponsor":"NRG Oncology","official_title":"A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2034-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival (PFS) at least 360 days after randomization (PFS360)","timeFrame":"From completing 360 days of maintenance therapy to disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version [v]1.1) or death, whichever occurs first, assessed up to 5 years"}],"references":[],"start_date":{"date":"2025-03-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer","url":"https://clinicaltrials.gov/study/NCT06580314"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nrg-gy036-nct06580314"}